Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2018 / N 2

Раннее выявление идиопатического легочного фиброза: дифференциальная диагностика с интерстициальными поражениями легких при системных иммуновоспалительных ревматических заболеваниях
Л.П. Ананьева, А.С. Белевский

References
1. Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet 2012 Aug;380(9842):689-98.
2. Kim EA, Lee KS, Johkoh T, Kim TS, Suh GY, Kwon OJ, Han J. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics 2002 Oct;22 Spec No:S151-65.
3. Cottin V. Significance of connective tissue diseases features in pulmonary fibrosis. European Respiratory Review 2013 Sep;22(129):273-80.
4. Mittoo S, Gelber AC, Christopher-Stine L, Horton MR, Lechtzin N, Danoff SK. Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respiratory Medicine 2009 Aug;103(8):1152-8.
5. Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest 2011 Nov;140(5):1292-9.
6. Alhamad Е.H Interstitial lung diseases in Saudi Arabia: a single-center study. Annals of Thoracic Medicine 2013 Jan;8(1):33-7.
7. Fischer A, West SG, Swigris JJ, Brown KK, Du Bois RM. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest 2010 Aug;138(2):251-6.
8. Lin Pan L, Liu Y, Sun R, Fan M, Shi G. Comparison of characteristics of connective tissue disease-associated interstitial lung diseases, undifferentiated connective tissue disease-associated interstitial lung diseases, and idiopathic pulmonary fibrosis in Chinese Han population: a retrospective study. Clinical and Developmental Immunology 2013;2013:121578.
9. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, Haslam PL, Vassilakis DA, Black CM, du Bois RM. Histologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. American Journal of Respiratory and Critical Care Medicine 2002 Jun;165(12):1581-6.
10. Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG, Colby TV. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. American Journal of Respiratory and Critical Care Medicine 2007 Apr;175(7):705-11.
11. Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden JH, Lee JS, King TE Jr, Collard HR. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. The European Respiratory Journal 2010 Jun;35(6):1322-8.
12. Su R, Bennett M, Jacobs S, Hunter T, Bailey C, Krishnan E, Rosen G, Chung L. An analysis of connective tissue disease-associated interstitial lung disease at a US Tertiary Care Center: better survival in patients with systemic sclerosis. Journal of Rheumatology 2011 Apr;38(4):693-701.
13. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet 2011 May;377(9779):1760-9.
14. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. The New England Journal of Medicine 2014 May;370(22):2083-92.
15. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. The New England Journal of Medicine 2014 May;370(22):2071-82.
16. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine 2011 Mar;183(6):788-824.
17. Thomeer M, Demedts M, Behr J, Buhl R, Costabel U, Flower CD, Verschakelen J, Laurent F, Nicholson AG, Verbeken EK, Capron F, Sardina M, Corvasce G, Lankhorst I. Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. The European Respiratory Journal 2008 Mar;31(3):585-91.
18. Cottin V. Idiopathic interstitial pneumonias with connective tissue diseases features: a review. Respirology 2016 Feb;21(2):245-258.
19. Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ 2016 Feb;352:h6819.
20. Rheumatology: Russian clinical guidelines. Nasonov EL, editor. Moscow: Geotar-Media; 2017. 464 p. (In Russian).
21. Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL, Mosca M, Noth I, Richeldi L, Strek ME, Swigris JJ, Wells AU, West SG, Collard HR, Cottin V; “ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD”. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. The European Respiratory Journal 2015 Oct;46(4):976-87.
22. Ferri C, Manfredi A, Sebastiani M, Colaci M, Giuggioli D, Vacchi C, Della Casa G, Cerri S, Torricelli P, Luppi F. Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: our interdisciplinary rheumatology-pneumology experience, and review of the literature. Autoimmunity Reviews 2016 Jan;15(1):61-70.
23. Oldham JM, Adegunsoye A, Valenzi E, Lee C, Witt L, Chen L, Husain AN, Montner S, Chung JH, Cottin V, Fischer A, Noth I, Vij R, Strek ME. Characterisation of patients with interstitial pneumonia with autoimmune features. The European Respiratory Journal 2016 Jun;47(6):1767-75.
24. Ananyeva LP. Multidisciplinary problems of rheumatology and pulmonology. Therapeutic Archive 2017;89(5):4-9 (In Russian).
25. Castellino F, Goldberg H, Dellaripa PF. The impact of rheumatologic evaluation in the management of patients with interstitial lung disease. Rheumatology (Oxford) 2011 Mar;50(3):483-93.
26. Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters EH, D’Amico R, Richeldi L. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database of Systematic Reviews 2010 Sep;(9):CD003134.
27. Meyer KC, Decker CA. Role of pirfenidone in the management of pulmonary fibrosis. Therapeutics and Clinical Risk Management 2017 Apr;13:427-37.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]